部長 斎藤 嘉朗 (さいとう よしろう、SAITO, Yoshiro)

客員研究員 長谷川 隆一 (はせがわ りゅういち、医薬品医療機器総合機構)

客員研究員 澤田純一 (さわだ じゅんいち、医薬品医療機器総合機構)

客員研究員 中垣 俊郎 なかがき としろう、京都府立医科大学大学院医学研究科 教授)

客員研究員 鹿庭 なほ子 (かにわ なほこ、日本医薬情報センター

客員研究員 頭金 正博 (とうきん まさひろ、名古屋市立大学 薬学部 教授)

客員研究員 黒瀬 光一 (くろせ こういち、東京海洋大学 教授)

協力研究員 三枝 大輔 (さえぐさ だいすけ、東北大学 東北メディカル・メガバンク機構 講師))

協力研究員 鳥谷部 貴祥 (とりやべ たかよし、医薬品医療機器総合機構 安全第二部 専門員)

協力研究員 川ア 淳史 (かわさき あつし、医薬品医療機器総合機構 安全第二部 専門員)

事務補助員 須藤 チエ (すどう ちえ、SUDO, Chie

 

―――――――――――――――――――――――――――――――

斎藤 嘉朗 (Yoshiro Saito [yoshiro @ nihs.go.jp] (スペース除いて下さい) Saito photo

最終出身大学院: 九州大学大学院薬学研究科 修士課程修了 

取得学位: 博士(薬学)(東京大学)

兼職: 東北大学大学院薬学研究科 客員教授(医薬品評価学講座)

     帝京平成大学大学院薬学研究科 客員教授

     名古屋市立大学大学院薬学研究科 客員教授

     京都府立医科大学 客員講師

所属学会: 日本薬物動態学会(理事)、日本レギュラトリーサイエンス学会(社員)

       日本免疫毒性学会(理事)、日本人類遺伝学会(薬理遺伝学委員会委員)、日本臨床薬理学会(社員)、

       日本毒性学会(Fund Toxicol Sci誌 編集委員、評議員)、日本TDM学会、

       日本薬剤疫学会、日本遺伝子診療学会、日本薬学会

研究分野: 医薬品副作用学、ゲノム薬理学、免疫毒性学、メタボローム、薬剤疫学

賞:     平成19年度日本薬学会薬学研究ビジョン部会賞

       日本免疫毒性学会第15回学術大会奨励賞(2008)

       日本薬物動態学会奨励賞(2009)

研究テーマ: 重篤副作用に関するバイオマーカー解析

       薬物アレルギーの発現機序の解明

       疾患および薬剤反応性関連代謝物のメタボローム解析

       医薬品の安全性に関する薬剤疫学的解析

ひとこと:「人の一生は重き荷を背負いて遠き道を行くがごとし」でも「不楽是如何」 

      「六然」と「六中観」  

 

最近の発表論文

2013年以降は、部のTop pageご参照下さい。

(2012年)

  1. Kurose K, Koizumi T, Nishikawa J, Maekawa K, Saito Y.: Quality requirements for genomic DNA preparations and storage conditions for a high-density oligonucleotide microarray. Biol Pharm Bull. 35: 1846-1848 (2012).
  2. Duan H, Yoshimura K, Kobayashi N, Sugiyama K, Sawada J, Saito Y, Morisseau C, Hammock BD, Akatsuka T.: Development of monoclonal antibodies to human microsomal epoxide hydrolase and analysis of "preneoplastic antigen"-like molecules. Toxicol Appl Pharmacol. 260: 17-26 (2012).
  3. Azuma Y, Hata K, Sai K, Udagawa R, Hirakawa A, Tohkin M, Ryushima Y, Makino Y, Yokote N, Morikawa N, Fujiwara Y, Saito Y, Yamamoto H.: Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. Biol Pharm Bull. 35: 717-724 (2012).
  4. Sudo C, Maekawa K, Kaniwa N, Segawa K, Saito Y: Current status of drug-induced liver disease based on reports of adverse reactions to PMDA in Japan. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. in press.
  5. Kurose K, Hiratsuka K, Ishiwata K, Nishikawa J, Nonen S, Azuma J, Kato M, Wakeno M, Okugawa G, Kinoshita T, Kurosawa T, Hasegawa R, Saito Y.: Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. Psychiatry Res. in press.
  6. Tada M, Ishii-Watabe A, Maekawa K, Fukushima-Uesaka H, Kurose K, Suzuki T, Kaniwa N, Sawada JI, Kawasaki N, Nakajima TE, Kato K, Yamada Y, Shimada Y, Yoshida T, Ura T, Saito M, Muro K, Doi T, Fuse N, Yoshino T, Ohtsu A, Saijo N, Okuda H, Hamaguchi T, Saito Y, Matsumura Y.: Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant. Immunogenetics. in press.
  7. Tohkin M, Kaniwa N, Saito Y, Sugiyama E, Kurose K, Nishikawa J, Hasegawa R, Aihara M, Matsunaga K, Abe M, Furuya H, Takahashi Y, Ikeda H, Muramatsu M, Ueta M, Sotozono C, Kinoshita S, Ikezawa Z.: A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. in press.
  8. 斎藤嘉朗: 副作用の予測・提言を目指して, 薬剤学, 72: 95-100 (2012).
  9. 有田誠,斎藤嘉朗, 田口良,西島正弘: メタボローム新技術が切り拓くこれからの脂質バイオロジー研究. 実験医学, 30: 446-454 (2012).
  10. 門脇京子, 石黒昭博, 高松昭司, 斎藤嘉朗, 宇山佳明: 本邦の医薬品添付文書におけるゲノム薬理学関連情報およびその検査法の状況に関する調査・解析. レギュラトリーサイエンス学会誌. 2: 83-92 (2012).
  11. 黒瀬光一、斎藤嘉朗: ゲノム情報に基づいた副作用予測. 日本臨床(医薬品副作用学(第2版) −薬剤の安全使用アップデート−), 1026: 18-24 (2012).
  12. 斎藤嘉朗、須藤チエ: スティーブンス・ジョンソン症候群(SJS)および中毒性表皮壊死症(TEN)の発生状況と原因薬剤. 日本医事新報, 4613, 60-61 (2012).
  13. 斎藤嘉朗、前川京子、鹿庭なほ子: 日本人を対象にしたゲノム・メタボローム解析によるバイオマーカー探索. Pharmstage, 2012.9, 1-4 (2012).

(2011年)

  1. Sato Y, Yamamoto N, Kunitoh H, Ohe Y, Minami H, Laird NM, Katori N, Saito Y, Ohnami S, Sakamoto H, Sawada JI, Saijo N, Yoshida T, Tamura T.: Genome-Wide Association Study on Overall Survival of Advanced Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel., J Thorac Oncol., 6: 132-138 (2011).
  2. Saito Y, Yamamoto N, Katori N, Maekawa K, Fukushima-Uesaka H, Sugimoto D, Kurose K, Sai K, Kaniwa N, Sawada JI, Kunitoh H, Ohe Y, Yoshida T, Matsumura Y, Saijo N, Okuda H, Tamura T.: Genetic polymorphisms and haplotypes of POR encoding cytochrome P450 oxidoreductase in a Japanese population. Drug Metab. Pharmacokinet., 26: 107-116 (2011)..
  3. Hanioka N, Matsumoto K,Saito Y and Narimatsu S: Influence of CYP2C8*13 and CYP2C8*14 Alleles on Amiodarone N-Deethylation. Basic Clin. Pharmacol. Toxicol., 108: 359-362 (2011)..
  4. Sai K. and Saito Y.: Ethnic differences in the metabolism and responses (toxicology and efficacy) of three anti-cancer drugs. Expert Opin. Drug Metab. Toxicol., 7: 967-988 (2011).
  5. Maekawa K, Hamaguchi T, Saito Y, Tatewaki N, Kurose K, Kaniwa N, Eguchi Nakajima T, Kato K, Yamada Y, Shimada Y, Yoshida T, Kamatani N, Ura T, Saito M, Muro K, Fuse N, Yoshino T, Doi T, Otsu A, Saijo N, Sawada J, Okuda H, Matsumura Y.: Genetic variation and haplotype structures of the glutathione S-transferase genes GSTA1 and GSTA2 in Japanese colorectal cancer patients. Drug Metab Pharmacokinet., 26:  646-658 (2011).
  6. atori N, Sai K, Saito Y, Fukushima-Uesaka H, Kurose K, Yomota C, Kawanishi T, Nishimaki-Mogami T, Naito M, Sawada JI, Kunitoh H, Nokihara H, Sekine I, Ohe Y, Yoshida T, Matsumura Y, Saijo N, Yamamoto N, Okuda H, Tamura T.: Genetic variations of orosomucoid genes associated with serum alpha-1-acid glycoprotein level and the pharmacokinetics of paclitaxel in Japanese cancer patients. J Pharm Sci. 100: 4546-4559 (2011).
  7. Sudo C, Azuma Y, Maekawa K, Kaniwa N, Sai K, Saito Y: Current movements of four serious adverse events induced by medicinal drugs based on spontaneous reports in Japan. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 129: 111-117 (2011).
  8. 斎藤嘉朗: 抗がん剤の副作用回避のためのPharmacogenomics (PGx) 研究. 薬学雑誌, 131: 239-246 (2011).

2010年).

  1. Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Matsumura Y, Ohtsu A, Saijo N, Minami H.: Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol. 66: 95-105 (2010).
  2. Matsubara J, Ono M, Honda K, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Shoji A, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T.: Survival prediction for pancreatic cancer patients receiving gemcitabine treatment. Mol Cell Proteomics. 9: 695-704 (2010).
  3. Ikeda H., Takahashi Y., Yamazaki E., Fujiwara T., Kaniwa N., Saito Y., Aihara M., Kashiwagi M. and Muramatsu M.: HLA-class ? markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia, 51: 297-300 (2010).
  4. Sugiyama E., Kaniwa N., Kim S.R., Hasegawa R.,Saito Y., Ueno H.,Okusaka T., Ikeda M., Morizane C., Kondo S., Yamamoto N., Tamura T., Furuse J., Ishii H., Yoshida T., Saijo N. and Sawada J.: Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: Impact of genetic polymorphisms. Clin. Pharmacokinet., 49: 549-558 (2010).
  5. Hanioka N., Matsumoto K.,Saito Y. and Narimatsu S.: Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel.  Basic Clin. Pharmacol. Toxicol., 107: 565-569 (2010).
  6. Sai K.,Saito Y., Tatewaki N., Hosokawa M., Kaniwa N., Nishimaki-Mogami T., Naito M., Sawada J., Shirao K., Hamaguchi T., Yamamoto N., Kunitoh H., Tamura T., Yamada Y., Ohe Y., Yoshida T., Minami H., Ohtsu A., Matsumura Y., Saijo N., Okuda H.: Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. Br. J. Clin. Pharmacol., 70: 222-233 (2010).
  7. Maekawa K., Harakawa N., Yoshimura T., Kim S.R., Fujimura Y., Aohara F., Sai K., Katori N., Tohkin M., Naito M., Hasegawa R., Okuda H., Sawada J., Niwa T. and Saito Y.: CYP3A4*16 and CYP3A4*18 Alleles Found in East Asians Exhibit Differential Catalytic Activities for Seven CYP3A4 Substrate Drugs. Drug metab. Dispos., 38: 2100-2104 (2010).
  8. Tohkin M, Ishiguro A, Kaniwa N, Saito Y, Kurose K, Hasegawa R.: Prediction of severe adverse drug reactions using pharmacogenetic biomarkers. Drug Metab. Pharmacokinet., 25: 122-133 (2010).
  9. Ishii-Watabe A, Saito Y, Suzuki T, Tada M, Ukaji M, Maekawa K, Kurose K, Kaniwa N, Sawada JI, Kawasaki N, Yamaguchi T, Eguchi Nakajima T, Kato K, Yamada Y, Shimada Y, Yoshida T, Ura T, Saito M, Muro K, Doi T, Fuse N, Yoshino T, Ohtsu A, Saijo N, Hamaguchi T, Okuda H, Matsumura Y.: Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis. Drug Metab. Pharmacokinet., 25: in press (2010).
  10. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R; JSAR research group.: HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 51: 2461-2465 (2010).
  11. 斎藤嘉朗, 奥田晴宏, 澤田純一: ファーマコゲノミクス解析 国立医薬品食品衛生研究所での10年. ファルマシア, 46: 403-408 (2009).
  12. 斎藤嘉朗、杉山永見子, 長谷川隆一 : 一塩基多型(SNP)解析. ぶんせき, 239-245 (2010).
  13. 斎藤嘉朗、佐井君江、澤田純一:薬剤副作用に関する遺伝子解析. 日本臨床, 68 Suppl 8 :263-268 (2010).

(2009)

  1. Ueno H, Kaniwa N, Okusaka T, Ikeda M, Morizane C, Kondo S, Sugiyama E, Kim SR, Hasegawa R, Saito Y, Yoshida T, Saijo N, Sawada J.: Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br J Cancer, 100: 870-873 (2009).
  2. Matsubara J, Ono M, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Honda K, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T.: Identification of a predictive biomarker for hematologic toxicities of gemcitabine. J Clin Oncol, 27: 2261-2268 (2009).
  3. Maekawa K, Yoshimura T, Saito Y, Fujimura Y, Aohara F, Emoto C, Iwasaki K, Hanioka N, Narimatsu S, Niwa T, Sawada J.: Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine. Xenobiotica, 39: 140-147 (2009).
  4. Tatewaki N, Maekawa K, Katori N, Kurose K, Kaniwa N, Yamamoto N, Kunitoh H, Ohe Y, Nokihara H, Sekine I, Tamura T, Yoshida T, Saijo N, Saito Y, Sawada J.: Genetic variations and haplotype structures of the glutathione S-transferase genes, GSTT1 and GSTM1, in a Japanese patient population. Drug Metab Pharmacokinet., 24: 118-126 (2009).
  5. Sato Y, Laird NM, Nagashima K, Kato R, Hamano T, Yafune A, Kaniwa N, Saito Y, Sugiyama E, Kim SR, Furuse J, Ishii H, Ueno H, Okusaka T, Saijo N, Sawada JI, Yoshida T.: A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies. Pharmacogenomics J. 9: 137-146 (2009)
  6. Saito Y, Sai K, Maekawa K, Kaniwa N, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Minami H, Ohtsu A, Matsumura Y, Saijo N, Sawada J.: Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug Metab Dispos., 37: 272-276 (2009).
  7. Sai K., Minami H., Saito Y. and Sawada J.: Impact of UDP-glucuronosyltransferase 1A haplotypes on irinotecan treatment.  Pharmacogenomics, Anticancer Drug Discovery, and Response (ed. F. Innocenti), Human Press, Totawa NJ, 2009, pp. 267-286.
  8. Sugiyama E, Lee SJ, Lee SS, Kim WY, Kim SR, Tohkin M, Hasegawa R, Okuda H, Kawamoto M, Kamatani N, Sawada J, Kaniwa N, Saito Y, Shin JG.: Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene. Drug Metab Pharmacokinet. 24: 553-556 (2009).
  9. Fukushima-Uesaka H, Saito Y, Maekawa K, Kurose K, Sugiyama E, Katori N, Kaniwa N, Hasegawa R, Hamaguchi T, Eguchi-Nakajima T, Kato K, Yamada Y, Shimada Y, Yoshida T, Yamamoto N, Nokihara H, Kunitoh H, Ohe Y, Tamura T, Ura T, Saito M, Muro K, Doi T, Fuse N, Yoshino T, Ohtsu A, Saijo N, Matsumura Y, Okuda H, Sawada J.: Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients. Drug Metab Pharmacokinet. 24: 565-574 (2009).
  10. 斎藤嘉朗, 澤田純一: ファーマコゲノミクス. 日本臨床, 67: 1175-1179 (2009).
  11. 前川京子, 斎藤嘉朗, 佐井君江, 澤田純一: 医薬品の応答性に関連する遺伝子多型 -抗血栓薬を中心に-. 血栓止血誌, 20: 27-36 (2009).
  12. 斎藤嘉朗, 前川京子, 澤田純一: 遺伝子多型解析. 日本臨床, 67, Suppl.1: 186-191 (2009).

 (2008)

  1. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R; JSAR research group.: HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics, 9: 1617-1622 (2008).
  2. Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, Ueno H, Okusaka T, Ikeda M, Morizane C, Yamamoto N, Yoshida T, Kamatani N, Furuse J, Ishii H, Saijo N, Ozawa S, Sawada J.: Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK). Drug Metab Pharmacokinet., 23:379-384 (2008).
  3. Hanioka N., Tsuneto Y., Saito Y., Maekawa K., Sawada J., Narimatsu S.: Influence of CYP2C19*18 and CYP2C19*19 Alleles on Omeprazole 5-Methylhydroxylation: In Vitro Functional Analysis of Recombinant Enzymes Expressed in Saccharomyces cerevisiae.Basic Clin. Pharmacol. Toxicol., 102: 388-393 (2008).
  4. Sai K., Saito Y., Sakamoto H., Shirao K., Kurose K., Saeki M., Ozawa S., Kaniwa N., Hirohashi S., Saijo N., Sawada J., Yoshida T.: Importance of UDP-glucuronosyltransferase 1A1 *6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett., 261: 165-171 (2008).
  5. Sai K., Saito Y., Itoda M., Fukushima-Uesaka H., Ozawa S., Kurose K., Kaniwa N.,  Kawamoto M., Kamatani N., Shirao K., Yamamoto N., Hamaguchi T., Kunitoh H., Ohe Y., Yamada Y., Tamura T., Yoshida T., Minami H., Matsumura Y., Ohtsu A., Saijo  N., J. Sawada: Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. Drug. Metab. Pharmacokinet., 23: 139-147 (2008).
  6. Sai K., Saito Y., Fukushima-Uesaka H., Kurose K., Kaniwa N., Kamatani N., Shirao K., Yamamoto N., Hamaguchi T., Kunitoh H., Ohe Y., Tamura T., Yamada Y., Minami H., Ohtsu A., Yoshida T., Saijo N., Sawada J.: Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemother. Pharmacol., 62: 529-537 (2008).
  7. Yin T., Maekawa K., Kamide K., Saito Y., Hanada H., Miyashita K., Kokubo Y., Akaiwa Y., Otsubo R., Nagatsuka K., Otsuki T., Horio T., Takiuchi S., Kawano Y., Minematsu K., Naritomi H., Tomoike H., Sawada J., Miyata T.: Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens. Res., 31: 1549-1557 (2008).
  8. 斎藤嘉朗、佐井君江: イリノテカンの副作用回避に向けたゲノム薬理学的アプローチ. 医学のあゆみ  225: 936-940 (2008).